Fosun (00656.HK): Fosun Pharma (02196.HK) reports 8.42% growth in non-recurring net profit for the first three quarters; globalization is turning from "narrative" into "profit"

Zhitong Finance APP has learned that the globalization of innovative drugs is transforming from a narrative that has been discussed for years into numbers that can be verified on the income statement. On October 27, Fosun International (00656.HK)'s core subsidiary in the health sector, Fosun Pharma, announced its performance for the first three quarters of 2026: operating revenue of RMB 30.463 billion, up 3.64% year on year; net profit attributable to shareholders of RMB 2.667 billion, up 5.71% year on year; and net profit attributable to shareholders after deducting non-recurring gains and losses of RMB 1.706 billion, up 8.42% year on year. Profit grew faster than revenue, and net profit after deducting non-recurring gains and losses grew faster than net profit attributable to shareholders. The core drivers were "continued growth in revenue from innovative drugs and steady improvement in operating efficiency."